Oxford Biomedica Announces Development Milestone in its Collaboration with Molmed
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Oxford BioMedica has announced that its partner MolMed has received regulatory approval to start a Phase III trial of TK therapy for high risk acute leukaemia.
Under a license agreement with Oxford BioMedica, MolMed’s TK therapy product employs Oxford BioMedica’s retroviral ex vivo gene delivery technology. The start of a Phase III trial of TK therapy triggers an undisclosed milestone payment to Oxford BioMedica.
